Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 96

1.

Pan-TAM Tyrosine Kinase Inhibitor BMS-777607 Enhances Anti-PD-1 mAb Efficacy in a Murine Model of Triple-Negative Breast Cancer.

Kasikara C, Davra V, Calianese D, Geng K, Spires TE, Quigley M, Wichroski M, Sriram G, Suarez-Lopez L, Yaffe MB, Kotenko SV, De Lorenzo MS, Birge RB.

Cancer Res. 2019 May 15;79(10):2669-2683. doi: 10.1158/0008-5472.CAN-18-2614. Epub 2019 Mar 15.

PMID:
30877108
2.

Sterile particle-induced inflammation is mediated by macrophages releasing IL-33 through a Bruton's tyrosine kinase-dependent pathway.

Mishra PK, Palma M, Buechel B, Moore J, Davra V, Chu N, Millman A, Hallab NJ, Kanneganti TD, Birge RB, Behrens EM, Rivera A, Beebe KS, Benevenia J, Gause WC.

Nat Mater. 2019 Mar;18(3):289-297. doi: 10.1038/s41563-018-0271-6. Epub 2019 Jan 21.

PMID:
30664693
3.

Tyro3, Axl, and Mertk receptors differentially participate in platelet activation and thrombus formation.

Zhou J, Yang A, Wang Y, Chen F, Zhao Z, Davra V, Suzuki-Inoue K, Ozaki Y, Birge RB, Lu Q, Wu Y.

Cell Commun Signal. 2018 Dec 12;16(1):98. doi: 10.1186/s12964-018-0308-0.

4.

ZEB2, a master regulator of the epithelial-mesenchymal transition, mediates trophoblast differentiation.

DaSilva-Arnold SC, Kuo CY, Davra V, Remache Y, Kim PCW, Fisher JP, Zamudio S, Al-Khan A, Birge RB, Illsley NP.

Mol Hum Reprod. 2019 Feb 1;25(2):61-75. doi: 10.1093/molehr/gay053.

PMID:
30462321
5.

Insulin-like growth factor receptor signaling in breast tumor epithelium protects cells from endoplasmic reticulum stress and regulates the tumor microenvironment.

Obr AE, Kumar S, Chang YJ, Bulatowicz JJ, Barnes BJ, Birge RB, Lazzarino DA, Gallagher E, LeRoith D, Wood TL.

Breast Cancer Res. 2018 Nov 20;20(1):138. doi: 10.1186/s13058-018-1063-2.

6.

MerTK signaling in macrophages promotes the synthesis of inflammation resolution mediators by suppressing CaMKII activity.

Cai B, Kasikara C, Doran AC, Ramakrishnan R, Birge RB, Tabas I.

Sci Signal. 2018 Sep 25;11(549). pii: eaar3721. doi: 10.1126/scisignal.aar3721.

7.

International conference on Cell Death in Cancer and Toxicology 2018 (CDCT-2018).

Ansari KM, Arany PR, Arama E, Larisch S, Birge RB, Chandra D.

Cell Commun Signal. 2018 Jun 28;16(1):34. doi: 10.1186/s12964-018-0238-x.

8.

Crk adaptor protein promotes PD-L1 expression, EMT and immune evasion in a murine model of triple-negative breast cancer.

Kumar S, Davra V, Obr AE, Geng K, Wood TL, De Lorenzo MS, Birge RB.

Oncoimmunology. 2017 Sep 27;7(1):e1376155. doi: 10.1080/2162402X.2017.1376155. eCollection 2017. Erratum in: Oncoimmunology. 2017 Dec 19;7(1):e1413845.

9.

Requirement of Gamma-Carboxyglutamic Acid Modification and Phosphatidylserine Binding for the Activation of Tyro3, Axl, and Mertk Receptors by Growth Arrest-Specific 6.

Geng K, Kumar S, Kimani SG, Kholodovych V, Kasikara C, Mizuno K, Sandiford O, Rameshwar P, Kotenko SV, Birge RB.

Front Immunol. 2017 Nov 10;8:1521. doi: 10.3389/fimmu.2017.01521. eCollection 2017.

10.

Efferocytosis of dying cells differentially modulate immunological outcomes in tumor microenvironment.

Kumar S, Calianese D, Birge RB.

Immunol Rev. 2017 Nov;280(1):149-164. doi: 10.1111/imr.12587. Review.

PMID:
29027226
11.

The Procoagulant Activity of Apoptotic Cells Is Mediated by Interaction with Factor XII.

Yang A, Chen F, He C, Zhou J, Lu Y, Dai J, Birge RB, Wu Y.

Front Immunol. 2017 Sep 25;8:1188. doi: 10.3389/fimmu.2017.01188. eCollection 2017.

12.

Crk Tyrosine Phosphorylation Regulates PDGF-BB-inducible Src Activation and Breast Tumorigenicity and Metastasis.

Kumar S, Lu B, Davra V, Hornbeck P, Machida K, Birge RB.

Mol Cancer Res. 2018 Jan;16(1):173-183. doi: 10.1158/1541-7786.MCR-17-0242. Epub 2017 Oct 3.

13.

Small molecule inhibitors block Gas6-inducible TAM activation and tumorigenicity.

Kimani SG, Kumar S, Bansal N, Singh K, Kholodovych V, Comollo T, Peng Y, Kotenko SV, Sarafianos SG, Bertino JR, Welsh WJ, Birge RB.

Sci Rep. 2017 Mar 8;7:43908. doi: 10.1038/srep43908.

14.

Phosphatidylserine Sensing by TAM Receptors Regulates AKT-Dependent Chemoresistance and PD-L1 Expression.

Kasikara C, Kumar S, Kimani S, Tsou WI, Geng K, Davra V, Sriram G, Devoe C, Nguyen KN, Antes A, Krantz A, Rymarczyk G, Wilczynski A, Empig C, Freimark B, Gray M, Schlunegger K, Hutchins J, Kotenko SV, Birge RB.

Mol Cancer Res. 2017 Jun;15(6):753-764. doi: 10.1158/1541-7786.MCR-16-0350. Epub 2017 Feb 9.

15.

Ligand Activation of TAM Family Receptors-Implications for Tumor Biology and Therapeutic Response.

Davra V, Kimani SG, Calianese D, Birge RB.

Cancers (Basel). 2016 Nov 29;8(12). pii: E107. Review.

16.

Normalization of TAM post-receptor signaling reveals a cell invasive signature for Axl tyrosine kinase.

Kimani SG, Kumar S, Davra V, Chang YJ, Kasikara C, Geng K, Tsou WI, Wang S, Hoque M, Boháč A, Lewis-Antes A, De Lorenzo MS, Kotenko SV, Birge RB.

Cell Commun Signal. 2016 Sep 6;14(1):19. doi: 10.1186/s12964-016-0142-1.

17.

Efferocytosis.

Kumar S, Birge RB.

Curr Biol. 2016 Jul 11;26(13):R558-R559. doi: 10.1016/j.cub.2016.01.059.

18.

Phosphatidylserine is a global immunosuppressive signal in efferocytosis, infectious disease, and cancer.

Birge RB, Boeltz S, Kumar S, Carlson J, Wanderley J, Calianese D, Barcinski M, Brekken RA, Huang X, Hutchins JT, Freimark B, Empig C, Mercer J, Schroit AJ, Schett G, Herrmann M.

Cell Death Differ. 2016 Jun;23(6):962-78. doi: 10.1038/cdd.2016.11. Epub 2016 Feb 26. Review.

19.

Cyclophilin A promotes cell migration via the Abl-Crk signaling pathway.

Saleh T, Jankowski W, Sriram G, Rossi P, Shah S, Lee KB, Cruz LA, Rodriguez AJ, Birge RB, Kalodimos CG.

Nat Chem Biol. 2016 Feb;12(2):117-23. doi: 10.1038/nchembio.1981. Epub 2015 Dec 14.

20.

Molecular and Translational Classifications of DAMPs in Immunogenic Cell Death.

Garg AD, Galluzzi L, Apetoh L, Baert T, Birge RB, Bravo-San Pedro JM, Breckpot K, Brough D, Chaurio R, Cirone M, Coosemans A, Coulie PG, De Ruysscher D, Dini L, de Witte P, Dudek-Peric AM, Faggioni A, Fucikova J, Gaipl US, Golab J, Gougeon ML, Hamblin MR, Hemminki A, Herrmann M, Hodge JW, Kepp O, Kroemer G, Krysko DV, Land WG, Madeo F, Manfredi AA, Mattarollo SR, Maueroder C, Merendino N, Multhoff G, Pabst T, Ricci JE, Riganti C, Romano E, Rufo N, Smyth MJ, Sonnemann J, Spisek R, Stagg J, Vacchelli E, Vandenabeele P, Vandenberk L, Van den Eynde BJ, Van Gool S, Velotti F, Zitvogel L, Agostinis P.

Front Immunol. 2015 Nov 20;6:588. doi: 10.3389/fimmu.2015.00588. eCollection 2015.

21.

Reciprocal regulation of Abl kinase by Crk Y251 and Abi1 controls invasive phenotypes in glioblastoma.

Kumar S, Lu B, Dixit U, Hossain S, Liu Y, Li J, Hornbeck P, Zheng W, Sowalsky AG, Kotula L, Birge RB.

Oncotarget. 2015 Nov 10;6(35):37792-807. doi: 10.18632/oncotarget.6096.

22.

Contribution of Defective PS Recognition and Efferocytosis to Chronic Inflammation and Autoimmunity.

Kimani SG, Geng K, Kasikara C, Kumar S, Sriram G, Wu Y, Birge RB.

Front Immunol. 2014 Nov 10;5:566. doi: 10.3389/fimmu.2014.00566. eCollection 2014. Review.

23.

Iterative tyrosine phosphorylation controls non-canonical domain utilization in Crk.

Sriram G, Jankowski W, Kasikara C, Reichman C, Saleh T, Nguyen KQ, Li J, Hornbeck P, Machida K, Liu T, Li H, Kalodimos CG, Birge RB.

Oncogene. 2015 Aug 6;34(32):4260-9. doi: 10.1038/onc.2014.361. Epub 2014 Nov 10.

24.

Overexpression of MERTK receptor tyrosine kinase in epithelial cancer cells drives efferocytosis in a gain-of-function capacity.

Nguyen KQ, Tsou WI, Calarese DA, Kimani SG, Singh S, Hsieh S, Liu Y, Lu B, Wu Y, Garforth SJ, Almo SC, Kotenko SV, Birge RB.

J Biol Chem. 2014 Sep 12;289(37):25737-49. doi: 10.1074/jbc.M114.570838. Epub 2014 Jul 29.

25.

Receptor tyrosine kinases, TYRO3, AXL, and MER, demonstrate distinct patterns and complex regulation of ligand-induced activation.

Tsou WI, Nguyen KQ, Calarese DA, Garforth SJ, Antes AL, Smirnov SV, Almo SC, Birge RB, Kotenko SV.

J Biol Chem. 2014 Sep 12;289(37):25750-63. doi: 10.1074/jbc.M114.569020. Epub 2014 Jul 29.

26.

High molecular weight kininogen binds phosphatidylserine and opsonizes urokinase plasminogen activator receptor-mediated efferocytosis.

Yang A, Dai J, Xie Z, Colman RW, Wu Q, Birge RB, Wu Y.

J Immunol. 2014 May 1;192(9):4398-408. doi: 10.4049/jimmunol.1302590. Epub 2014 Mar 31.

27.

Crk at the quarter century mark: perspectives in signaling and cancer.

Kumar S, Fajardo JE, Birge RB, Sriram G.

J Cell Biochem. 2014 May;115(5):819-25. doi: 10.1002/jcb.24749.

PMID:
24356912
28.

TAM receptors in apoptotic cell clearance, autoimmunity, and cancer.

Nguyen KQ, Tsou WI, Kotenko S, Birge RB.

Autoimmunity. 2013 Aug;46(5):294-7. doi: 10.3109/08916934.2013.794515. Epub 2013 May 10. Review.

PMID:
23662598
29.

ATG proteins mediate efferocytosis and suppress inflammation in mammary involution.

Teplova I, Lozy F, Price S, Singh S, Barnard N, Cardiff RD, Birge RB, Karantza V.

Autophagy. 2013 Apr;9(4):459-75. doi: 10.4161/auto.23164. Epub 2013 Feb 4.

30.

Crk and ABI1: binary molecular switches that regulate abl tyrosine kinase and signaling to the cytoskeleton.

Hossain S, Dubielecka PM, Sikorski AF, Birge RB, Kotula L.

Genes Cancer. 2012 May;3(5-6):402-13. doi: 10.1177/1947601912460051.

31.

Monographs editor.

Birge RB.

Genes Cancer. 2012 May;3(5-6):331. doi: 10.1177/1947601912460548. No abstract available.

32.

Commentary: The carboxyl-terminal Crk SH3 domain: Regulatory strategies and new perspectives.

Sriram G, Birge RB.

FEBS Lett. 2012 Aug 14;586(17):2615-8. doi: 10.1016/j.febslet.2012.04.040. Epub 2012 May 2. Review.

33.

Domain organization differences explain Bcr-Abl's preference for CrkL over CrkII.

Jankowski W, Saleh T, Pai MT, Sriram G, Birge RB, Kalodimos CG.

Nat Chem Biol. 2012 May 13;8(6):590-6. doi: 10.1038/nchembio.954.

34.

Externalized glycolytic enzymes are novel, conserved, and early biomarkers of apoptosis.

Ucker DS, Jain MR, Pattabiraman G, Palasiewicz K, Birge RB, Li H.

J Biol Chem. 2012 Mar 23;287(13):10325-43. doi: 10.1074/jbc.M111.314971. Epub 2012 Jan 18.

35.

Emerging roles for crk in human cancer.

Sriram G, Birge RB.

Genes Cancer. 2010 Nov;1(11):1132-9. doi: 10.1177/1947601910397188.

36.

Phosphorylation of Crk on tyrosine 251 in the RT loop of the SH3C domain promotes Abl kinase transactivation.

Sriram G, Reichman C, Tunceroglu A, Kaushal N, Saleh T, Machida K, Mayer B, Ge Q, Li J, Hornbeck P, Kalodimos CG, Birge RB.

Oncogene. 2011 Nov 17;30(46):4645-55. doi: 10.1038/onc.2011.170. Epub 2011 May 23.

37.

Sphingosine kinase 1 overexpression is regulated by signaling through PI3K, AKT2, and mTOR in imatinib-resistant chronic myeloid leukemia cells.

Marfe G, Di Stefano C, Gambacurta A, Ottone T, Martini V, Abruzzese E, Mologni L, Sinibaldi-Salimei P, de Fabritis P, Gambacorti-Passerini C, Amadori S, Birge RB.

Exp Hematol. 2011 Jun;39(6):653-665.e6. doi: 10.1016/j.exphem.2011.02.013. Epub 2011 Mar 8.

PMID:
21392556
38.

Structural basis for regulation of the Crk signaling protein by a proline switch.

Sarkar P, Saleh T, Tzeng SR, Birge RB, Kalodimos CG.

Nat Chem Biol. 2011 Jan;7(1):51-7. doi: 10.1038/nchembio.494. Epub 2010 Dec 5.

39.

Real-time fluorescent resonance energy transfer analysis to monitor drug resistance in chronic myelogenous leukemia.

Tunceroglu A, Matsuda M, Birge RB.

Mol Cancer Ther. 2010 Nov;9(11):3065-73. doi: 10.1158/1535-7163.MCT-10-0623. Epub 2010 Sep 3.

40.

Apoptosis: conserved roles for integrins in clearance.

D'mello V, Birge RB.

Curr Biol. 2010 Apr 13;20(7):R324-7. doi: 10.1016/j.cub.2010.02.043.

41.

Control of Alzheimer's amyloid beta toxicity by the high molecular weight immunophilin FKBP52 and copper homeostasis in Drosophila.

Sanokawa-Akakura R, Cao W, Allan K, Patel K, Ganesh A, Heiman G, Burke R, Kemp FW, Bogden JD, Camakaris J, Birge RB, Konsolaki M.

PLoS One. 2010 Jan 13;5(1):e8626. doi: 10.1371/journal.pone.0008626.

42.

International Cell Death Society annual meeting 2009.

Birge RB, Cronje MJ, Lockshin RA, Zakeri Z.

Cell Death Differ. 2010 Jan;17(1):187. doi: 10.1038/cdd.2009.151. No abstract available.

43.

Regeneration after death: Vav3 to the rescue.

D'mello V, Birge RB.

Blood. 2009 May 21;113(21):5037-8. doi: 10.1182/blood-2009-02-203265. No abstract available.

44.

Crk and CrkL adaptor proteins: networks for physiological and pathological signaling.

Birge RB, Kalodimos C, Inagaki F, Tanaka S.

Cell Commun Signal. 2009 May 10;7:13. doi: 10.1186/1478-811X-7-13.

45.

The urokinase plasminogen activator receptor promotes efferocytosis of apoptotic cells.

D'mello V, Singh S, Wu Y, Birge RB.

J Biol Chem. 2009 Jun 19;284(25):17030-8. doi: 10.1074/jbc.M109.010066. Epub 2009 Apr 21.

46.

Transglutaminase 2 is needed for the formation of an efficient phagocyte portal in macrophages engulfing apoptotic cells.

Tóth B, Garabuczi E, Sarang Z, Vereb G, Vámosi G, Aeschlimann D, Blaskó B, Bécsi B, Erdõdi F, Lacy-Hulbert A, Zhang A, Falasca L, Birge RB, Balajthy Z, Melino G, Fésüs L, Szondy Z.

J Immunol. 2009 Feb 15;182(4):2084-92. doi: 10.4049/jimmunol.0803444.

47.

Innate apoptotic immunity: the calming touch of death.

Birge RB, Ucker DS.

Cell Death Differ. 2008 Jul;15(7):1096-102. doi: 10.1038/cdd.2008.58. Epub 2008 May 2. Review.

49.

A NPxY-independent beta5 integrin activation signal regulates phagocytosis of apoptotic cells.

Singh S, D'mello V, van Bergen en Henegouwen P, Birge RB.

Biochem Biophys Res Commun. 2007 Dec 21;364(3):540-8. Epub 2007 Oct 17.

50.

Proapoptotic function of the nuclear Crk II adaptor protein.

Kar B, Reichman CT, Singh S, O'Connor JP, Birge RB.

Biochemistry. 2007 Sep 25;46(38):10828-40. Epub 2007 Sep 1.

PMID:
17764157

Supplemental Content

Loading ...
Support Center